[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336570-105":59,"doc-detail-336570-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","patient-centric-thresholding-of-cobas-egfr-mutation-test-v2-for-surveillance-of-egfr-mutated-metastatic-non-small-cell-lung-cancer","Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer","","Cobas EGFR mutation Test v2 provides semiquantitative SQI values for actionable EGFR variants in non-small cell lung cancer, yet clinical decision thresholds for surveillance are not established. Long-term ctDNA monitoring was conducted in 20 subjects with EGFR-mutated NSCLC, yielding 155 on-treatment samples. Optimal SQI intervals were defined to predict or rule out progression within 12 weeks, validated by orthogonal calibration against deep sequencing and digital PCR.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/patient-centric-thresholding-of-cobas-egfr-mutation-test-v2-for-surveillance-of-egfr-mutated-metastatic-non-small-cell-lung-cancer/336570/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/patient-centric-thresholding-of-cobas-egfr-mutation-test-v2-for-surveillance-of-egfr-mutated-metastatic-non-small-cell-lung-cancer/336570.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address for Cobas EGFR mutation Test v2?","Question",{"text":112,"@type":113},"The study targets the lack of established clinical SQI decision thresholds for using the test in NSCLC surveillance to predict or rule out progression within a defined time window.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was ctDNA monitoring performed in the study?",{"text":117,"@type":113},"Twenty subjects with EGFR-mutated NSCLC were followed with long-term ctDNA monitoring, generating 155 on-treatment samples for SQI-based analysis.",{"name":119,"@type":110,"acceptedAnswer":120},"How did SQI perform for diagnosing progression?",{"text":121,"@type":113},"SQI demonstrated significant diagnostic power and supported practical cutoffs: values below 5 provided high NPV, while values above 10 supported PPV for progression within 12 weeks.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336570,1791114863,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPatient‑centric thresholdingofCobas® EGFR mutation Test v2 for surveillance of EGFR‑mutated metastatic non‑small cell lung cancer  \nJonas Claus1,5, Dieter De Smet2,5, Joke Breyne2, Janusz Wesolowski3, Ulrike Himpe1, Ingel Demedts1 & Geert A. Martens2,4*  \nCobas EGFR mutation Test v2 was FDA‑approved as qualitative liquid biopsy for actionable EGFR variants in non‑small cell lung cancer (NSCLC). It generates semiquantitative index (SQI) values that correlate with mutant allele levels, but decision thresholds for clinical use in NSCLC surveillance are lacking. We conducted long‑term ctDNA monitoring in 20 subjects with EGFR‑mutated NSCLC; resulting in a 155 on‑treatment samples. We defined optimal SQI intervals to predict/rule‑out progression within 12 weeks from sampling and performed orthogonal calibration versus deep‑ sequencing and digital PCR. SQI showed significant diagnostic power (AUC 0.848, 95% CI 0.782–  \n0.901). SQI below 5 (63% of samples) had 93%(95% CI 87–96%) NPV, while SQI above 10 (25% of samples) had 69%(95% CI 56–80%) PPV. Cobas EGFR showed perfect agreement with sequencing (Kappa 0.860; 95% CI 0.674–1.00) and digital PCR. SQI values strongly (r: 0.910, 95% 0.821–0.956) correlated to mutant allele concentrations with SQI of 5 and 10 corresponding to 6–9 (0.2–0.3%) and 64–105 (1.1–1.6%) mutant allele copies/mL (VAF) respectively. Our dual‑threshold classifier of SQI 0/5/10 yielded informative results in 88% of blood draws with high NPV and good overall clinical utility for patient‑centric surveillance of metastatic NSCLC.  \nKeywords Diagnostic techniques and procedures, Clinical laboratory techniques, Liquid biopsy, Circulating tumor DNA, Biomarkers, Tumor, Statistics and numerical data, Carcinoma non-small-cell lung, Disease progression, Likelihood functions, ROC curve  \nAbbreviations  \nAUC Area under the Receiver Operating Characteristics (ROC) curve ctDNA Circulating tumor DNA  \nCI Confidence interval  \ndPCR Digital PCR  \nEGFR Epithelial growth factor receptor gene  \nLR Likelihood ratio  \nNPV Negative predictive value NSCLC Non-small cell lung cancer PCR Polymerase chain reaction PPV Positive predictive value PSS Plasma-SeqSensei™  \nSQI Semiquantitative index  \n1Department of Pulmonary Diseases, AZ Delta General Hospital, Roeselare, Belgium. 2Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium. 3Sysmex Inostics GmbH, Sysmex Corporation, Hamburg, Germany. 4Department of Biomolecular Medicine, Ghent University, Gent, Belgium. 5These authors contributed equally: Jonas Claus and Dieter De Smet.* email: [geert.martens@azdelta.be](geert.martens@azdelta.be)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nCirculating tumor (ctDNA) is increasingly used for cancer diagnosis and monitoring. ESMO and ASCO recognize the clinical utility of liquid biopsy for diagnostic purposes and to identify actionable mutations, but position tumor tissue genotyping still as first choice given its higher sensitivity1,2. For surveillance of advanced cancersand monitoring of therapy efficacy, ASCO and ESMO call for more data on assay interoperability and clinical validity of ctDNA levels1,3,4. Most studies on ctDNA for surveillance of advanced cancers have two limitations. First, ctDNA was mostly used qualitatively, without leveraging the diagnostic value of ctDNA concentrations. Second, data analysis was limited to proportional hazards modeling at cohort level. The latter statistical approach is useful to investigate the prognostic value of increasing ctDNA levels5 or to monitor therapeutic efficacy, but conveys no guidance for individual patients.  \nWe recently introduced a simple and patient-centred statistical approach to exploit the diagnostic value of absolute ctDNA concentrations for surveillance of metastatic breast cancers6. In a prospective observational trial (PrecisionTrack), we performed lo","cbCaiqrk4Y653iti","https://ap.wps.com/l/cbCaiqrk4Y653iti","pdf",1419835,"English","# Abstract\n## Diagnostic performance and thresholds\n## Correlation with mutant allele levels\n## Patient-centric surveillance framework\n## Study context and limitations of prior work","[{\"question\":\"What problem does the study address for Cobas EGFR mutation Test v2?\",\"answer\":\"The study targets the lack of established clinical SQI decision thresholds for using the test in NSCLC surveillance to predict or rule out progression within a defined time window.\"},{\"question\":\"How was ctDNA monitoring performed in the study?\",\"answer\":\"Twenty subjects with EGFR-mutated NSCLC were followed with long-term ctDNA monitoring, generating 155 on-treatment samples for SQI-based analysis.\"},{\"question\":\"How did SQI perform for diagnosing progression?\",\"answer\":\"SQI demonstrated significant diagnostic power and supported practical cutoffs: values below 5 provided high NPV, while values above 10 supported PPV for progression within 12 weeks.\"}]","Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer | PDF",1790015664,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c971fc68eece5184858c222ce27f118.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4248ce1e453a5fbd1b4c4a7074d2224b.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73c18fb45462c2d7a1efec871bcd5398.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9589e3b54a255d072e80ee5988630e97.webp",980,1287]